Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
نویسندگان
چکیده
Acquired genomic aberrations have been shown to significantly impact survival in several hematologic malignancies. We analyzed the prognostic value of the most frequent chromosomal changes in a large series of patients with newly diagnosed symptomatic myeloma prospectively enrolled in homogeneous therapeutic trials. All the 1064 patients enrolled in the IFM99 trials conducted by the Intergroupe Francophone du Myélome benefited from an interphase fluorescence in situ hybridization analysis performed on purified bone marrow plasma cells. They were systematically screened for the following genomic aberrations: del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p). Chromosomal changes were observed in 90% of the patients. The del(13), t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p) were present in 48%, 21%, 14%, 39%, 13%, and 11% of the patients, respectively. After a median follow-up of 41 months, univariate statistical analyses revealed that del(13), t(4;14), nonhyperdiploidy, and del(17p) negatively impacted both the event-free survival and the overall survival, whereas t(11;14) and MYC translocations did not influence the prognosis. Multivariate analyses on 513 patients annotated for all the parameters showed that only t(4;14) and del(17p) retained prognostic value for both the event-free and overall survivals. When compared with the currently used International Staging System, this prognostic model compares favorably. In myeloma, the genomic aberrations t(4;14) and del(17p), together with beta2-microglobulin level, are important independent predictors of survival. These findings have implications for the design of risk-adapted treatment strategies.
منابع مشابه
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.
PURPOSE Chromosomal abnormalities, especially t(4;14) and del(17p), are major prognostic factors in patients with multiple myeloma (MM). However, this has been especially demonstrated in patients age < 66 years treated with intensive approaches. The goal of this study was to address this issue in elderly patients treated with conventional-dose chemotherapy. PATIENTS AND METHODS To answer this...
متن کاملComparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
High-dose therapy has become a common treatment for myeloma. The objective of this study (Intergroupe Francophone du Myélome [IFM] 9502 trial) was to compare in a prospective and randomized trial the 2 most widely used conditioning regimens before autologous stem cell transplantation in newly diagnosed symptomatic patients younger than 65 years old: 8 Gy total body irradiation plus 140 mg/m(2) ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)
Murielle Roussel,1 Philippe Moreau,2 Anne Huynh,1 Jean-Yves Mary,3 Clotaire Danho,1 Denis Caillot,4 Cyrille Hulin,5 Christophe Fruchart,6 Gérald Marit,7 Brigitte Pégourié,8 Pascal Lenain,9 Carla Araujo,10 Brigitte Kolb,11 Edouard Randriamalala,12 Bruno Royer,13 Anne-Marie Stoppa,14 Mammoun Dib,15 Véronique Dorvaux,16 Laurent Garderet,17 Claire Mathiot,18 Hervé Avet-Loiseau,2 Jean-Luc Harousseau...
متن کاملLYMPHOID NEOPLASIA Brief report Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Hervé Avet-Loiseau,1 Florent Malard,1 Loic Campion,2 Florence Magrangeas,1 Catherine Sebban,3 Bruno Lioure,4 Olivier Decaux,5 Thierry Lamy,6 Laurence Legros,7 Jean-Gabriel Fuzibet,8 Mauricette Michallet,9 Bernadette Corront,10 Pascal Lenain,11 Cyrille Hulin,12 Claire Mathiot,13 Michel Attal,14 Thierry Facon,15 Jean-Luc Harousseau,16 Stephane Minvielle,1 and Philippe Moreau,17 for the Intergroup...
متن کاملCytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique.
Primary plasma cell leukemia (PCL) is a rare plasma cell malignancy. Consequently, few large reports have been published. Presented is a cytogenetic analysis of 40 patients with primary PCL compared with 247 newly diagnosed patients with stage III multiple myeloma (MM). Cytogenetic abnormalities were observed in 23 of 34 patients, with usually complex hypodiploid or pseudodiploid karyotypes. An...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Blood
دوره 109 8 شماره
صفحات -
تاریخ انتشار 2007